Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Nano Dimension Ltd - ADR — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $227.23 (market cap $29.97B), while Nano Dimension Ltd - ADR trades at $1.62 (market cap $342.07M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 87.6× Nano Dimension Ltd - ADR's market cap, and Nano Dimension Ltd - ADR is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | NNDM | |
|---|---|---|
Market Cap | $29.97B | $342.07M |
Sector | Health | Technology |
52-Week High | $491.22 | $2.14 |
52-Week Low | $205.48 | $1.21 |
Enterprise Value | $27.93B | -$62.77M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $227.12, up 2.68% in the last 24 hours, but technical indicators signal a bearish trend with resistance near $229. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with a net income of $313.75M, though recent Q2 2026 earnings missed estimates. Multiple law firms are investigating potential securities fraud, adding to negative sentiment.
Outlook is mixed: analyst consensus remains bullish with a $370.07 price target, but risks include ongoing legal probes, earnings volatility, and high valuation multiples. The stock faces near-term pressure from bearish technicals and investor caution despite solid fundamental progress.
NNDM trades at $1.65, down 0.6% with a bullish technical signal from moving averages. The company shows revenue growth from $58M in 2024 to $102M in 2025 but faces significant profitability challenges with a net income margin of -135.18% and negative cash flow from operations. Recent strategic actions include cost-saving initiatives and the planned sale of MarkForged to Stratasys, aiming to reduce cash burn by $25M annually.
The outlook remains speculative due to persistent losses and cash burn, though asset sales and restructuring may stabilize finances. Investment opportunity hinges on successful execution of turnaround plans, while risks include ongoing operational losses, shareholder activism from Murchinson, and execution risks in strategic transitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →
